Announced today that, starting January 20, its $5 Tuesdays return for a limited time, running through ...
SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced...
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera ...
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants...
TORONTO , Dec. 16, 2025 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLA TM (fruquintinib capsules) will now be reimbursed by BC Cancer as a treatment option for...
Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The 2025 American Society of Hematology meeting showcased pivotal advances in blood cancer treatment, with...
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety Signals ...
− Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 Months After Last Dose 1 ...
Findings Reinforce QDENGA’s Long-Term Safety Profile and Two-Dose Vaccination Schedule QDENGA is the Longest-Studied...
First Half Revenue Declined 3.9% at Constant Exchange Rate (CER), -6.9% at Actual Exchange Rates (AER), Impacted by Generic...